Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study

Journal of Immunotherapy and Precision Oncology · Published 2026-07-17 · DOI 10.36401/jipo-26-11

Free full text

Authors (12)

Mohammad Aldawoud, Fatima Faqihi, Najd Algazlan, Marwa Alharbi, Abdullah Almazyad, Abdulaziz Altamimi, Mojahed Rudaini, Abdullah Alwohaibi, Besher Alghazi, Abdulrahman Alturki, Hatoon Bakhribah, Abdullah Altwairgi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Aldawoud, M., Faqihi, F., Algazlan, N., et al. (2026). Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study. Journal of Immunotherapy and Precision Oncology. https://doi.org/10.36401/jipo-26-11

Related articles